Cymabay Therapeutics, Inc. (CBAY) Is At $9.14 Formed Wedge; Live Nation Entertainment, Inc. (LYV) Covered By 10 Bullish Analysts Last Week

Among 14 analysts covering Live Nation (NYSE:LYV), 10 have Buy rating, 0 Sell and 4 Hold. Therefore 71% are positive. Live Nation had 22 analyst reports since September 18, 2015 according to SRatingsIntel. Citigroup initiated Live Nation Entertainment, Inc. (NYSE:LYV) on Thursday, October 8 with “Buy” rating. The rating was upgraded by Albert Fried to “Overweight” on Friday, October 30. Gabelli initiated the stock with “Buy” rating in Friday, September 18 report. Citigroup maintained the shares of LYV in report on Wednesday, October 12 with “Buy” rating. The stock of Live Nation Entertainment, Inc. (NYSE:LYV) earned “Buy” rating by Stephens on Thursday, August 10. The stock of Live Nation Entertainment, Inc. (NYSE:LYV) earned “Equal-Weight” rating by Stephens on Thursday, October 6. Macquarie Research maintained Live Nation Entertainment, Inc. (NYSE:LYV) rating on Wednesday, August 9. Macquarie Research has “Buy” rating and $4400 target. The rating was downgraded by Evercore to “In-Line” on Monday, November 20. The firm has “Hold” rating by Citigroup given on Friday, December 22. The rating was maintained by Jefferies on Monday, June 5 with “Buy”. See Live Nation Entertainment, Inc. (NYSE:LYV) latest ratings:

22/12/2017 Broker: Citigroup Rating: Hold New Target: $47.0 Downgrade
20/11/2017 Broker: Evercore Old Rating: Outperform New Rating: In-Line Downgrade
02/11/2017 Broker: Jefferies Rating: Buy New Target: $46.0 Maintain
16/10/2017 Broker: Jefferies Rating: Buy New Target: $42.0 Maintain
11/09/2017 Broker: Jefferies Rating: Buy New Target: $42.0 Maintain
11/08/2017 Broker: J.P. Morgan Rating: Buy
10/08/2017 Broker: Stephens Rating: Buy New Target: $44.0000 Maintain
09/08/2017 Broker: Macquarie Research Rating: Buy New Target: $44.0000 Maintain
21/07/2017 Broker: William Blair Rating: Outperform Initiates Coverage On

Cymabay Therapeutics, Inc. (CBAY) formed wedge up with $9.96 target or 9.00% above today’s $9.14 share price. Cymabay Therapeutics, Inc. (CBAY) has $400.92 million valuation. The stock decreased 2.25% or $0.21 during the last trading session, reaching $9.14. About 101,077 shares traded. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has risen 69.26% since January 9, 2017 and is uptrending. It has outperformed by 52.56% the S&P500.

Investors sentiment increased to 1.54 in Q3 2017. Its up 0.11, from 1.43 in 2017Q2. It improved, as 23 investors sold Live Nation Entertainment, Inc. shares while 89 reduced holdings. 65 funds opened positions while 107 raised stakes. 135.10 million shares or 4.62% more from 129.13 million shares in 2017Q2 were reported. Keybank Natl Association Oh reported 0.01% in Live Nation Entertainment, Inc. (NYSE:LYV). Putnam Invs Limited Liability, a Massachusetts-based fund reported 4.24 million shares. Landscape Capital Management Ltd Llc stated it has 0.34% in Live Nation Entertainment, Inc. (NYSE:LYV). Fiera Cap owns 795,670 shares. Bessemer Grp Inc Inc holds 0% in Live Nation Entertainment, Inc. (NYSE:LYV) or 2,300 shares. American Intll Group Inc invested in 0.04% or 274,113 shares. 821,297 were accumulated by Jennison Associate Limited Company. Rwc Asset Llp accumulated 320,920 shares. Sei Invests has 312,701 shares. First Personal Service, a North Carolina-based fund reported 980 shares. Product Ptnrs holds 0.62% in Live Nation Entertainment, Inc. (NYSE:LYV) or 427,300 shares. Penn Cap Mgmt Communications owns 73,712 shares or 0.24% of their US portfolio. Mutual Of America Capital Mgmt Limited Liability Corporation owns 0.08% invested in Live Nation Entertainment, Inc. (NYSE:LYV) for 110,656 shares. Public Employees Retirement Association Of Colorado reported 29,342 shares. Sterling Capital Ltd Liability Corp has 1.71M shares.

The stock increased 0.88% or $0.38 during the last trading session, reaching $43.43. About 73,653 shares traded. Live Nation Entertainment, Inc. (NYSE:LYV) has risen 52.18% since January 9, 2017 and is uptrending. It has outperformed by 35.48% the S&P500.

Since September 8, 2017, it had 0 insider purchases, and 2 selling transactions for $719,350 activity. 7,500 shares were sold by Capo Brian, worth $303,750. Another trade for 10,000 shares valued at $415,600 was made by Emanuel Ariel on Thursday, September 14.

Live Nation Entertainment, Inc. operates as a live entertainment company. The company has market cap of $8.98 billion. The firm operates through Concerts, Sponsorship & Advertising, Ticketing, and Artist Nation divisions. It has a 638.68 P/E ratio. The Concerts segment promotes live music events in its owned and/or operated venues, and in rented third-party venues; operates and manages music venues; and produces music festivals and creates associated content.

Among 6 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc has $16.0 highest and $2.25 lowest target. $12.80’s average target is 40.04% above currents $9.14 stock price. Cymabay Therapeutics Inc had 16 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Piper Jaffray with “Buy” on Monday, July 17. The firm earned “Neutral” rating on Wednesday, June 1 by H.C. Wainwright. The stock of Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has “Neutral” rating given on Wednesday, January 4 by H.C. Wainwright. The stock has “Buy” rating by Cantor Fitzgerald on Tuesday, September 19. The rating was initiated by Roth Capital with “Buy” on Friday, July 1. The stock has “Buy” rating by H.C. Wainwright on Tuesday, September 8. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, October 25 report. The rating was maintained by Piper Jaffray with “Buy” on Monday, September 11. Piper Jaffray maintained Cymabay Therapeutics, Inc. (NASDAQ:CBAY) on Tuesday, July 25 with “Buy” rating. The rating was maintained by Leerink Swann on Tuesday, November 28 with “Buy”.

Analysts await Cymabay Therapeutics, Inc. (NASDAQ:CBAY) to report earnings on March, 22. They expect $-0.13 EPS, up 56.67% or $0.17 from last year’s $-0.3 per share. After $-0.21 actual EPS reported by Cymabay Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -38.10% EPS growth.